1
|
Mattila MM, Ruohola JK, Valve EM, Tasanen
MJ, Seppänen JA and Härkönen PL: FGF-8b increases angiogenic
capacity and tumor growth of androgen-regulated S115 breast cancer
cells. Oncogene. 20:2791–2804. 2001. View Article : Google Scholar : PubMed/NCBI
|
2
|
Valta MP, Tuomela J, Vuorikoski H, Loponen
N, Väänänen RM, Pettersson K, Väänänen HK and Härkönen PL: FGF-8b
induces growth and rich vascularization in an orthotopic PC-3 model
of prostate cancer. J Cell Biochem. 107:769–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ruohola JK, Viitanen TP, Valve EM,
Seppänen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT and Härkönen
PL: Enhanced invasion and tumor growth of fibroblast growth factor
8b-overexpressing MCF-7 human breast cancer cells. Cancer Res.
61:4229–4237. 2001.PubMed/NCBI
|
4
|
Tuomela J, Grönroos TJ, Valta MP, Sandholm
J, Schrey A, Seppänen J, Marjamäki P, Forsback S, Kinnunen I, Solin
O, et al: Fast growth associated with aberrant vasculature and
hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3
prostate tumour xenografts. BMC Cancer. 10:5962010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Valve E, Martikainen P, Seppänen J,
Oksjoki S, Hinkka S, Anttila L, Grenman S, Klemi P and Härkönen P:
Expression of fibroblast growth factor (FGF)-8 isoforms and FGF
receptors in human ovarian tumors. Int J Cancer. 88:718–725. 2000.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Maruyama-Takahashi K, Shimada N, Imada T,
Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S,
Tanaka A and Shitara K: A neutralizing anti-fibroblast growth
factor (FGF) 8 monoclonal antibody shows anti-tumor activity
against FGF8b-expressing LNCaP xenografts in androgen-dependent and
-independent conditions. Prostate. 68:640–650. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Mattila MM and Härkönen PL: Role of
fibroblast growth factor 8 in growth and progression of hormonal
cancer. Cytokine Growth Factor Rev. 18:257–266. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Valta MP, Tuomela J, Bjartell A, Valve E,
Väänänen HK and Härkönen P: FGF-8 is involved in bone metastasis of
prostate cancer. Int J Cancer. 123:22–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Li T, Luo W, He D, Wang R, Huang Y, Zeng
X, Wang W, Chen X, Gao S, Yu Y, et al: A short peptide derived from
the gN helix domain of FGF8b suppresses the growth of human
prostate cancer cells. Cancer Lett. 339:226–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hadari Y, Gotoh N, Kouhara H, Lax I and
Schlessinger J: Critical role for the docking-protein FRS2α in FGF
receptor-mediated signal transduction pathways. Proc Natl Acad Sci
USA. 98:8578–8583. 2001. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ong SH, Guy GR, Hadari YR, Laks S, Gotoh
N, Schlessinger J and Lax I: FRS2 proteins recruit intracellular
signaling pathways by binding to diverse targets on fibroblast
growth factor and nerve growth factor receptors. Mol Cell Biol.
20:979–989. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yang X, Qiao D, Meyer K and Friedl A:
Signal transducers and activators of transcription mediate
fibroblast growth factor-induced vascular endothelial
morphogenesis. Cancer Res. 69:1668–1677. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yang X, Qiao D, Meyer K, Pier T, Keles S
and Friedl A: Angiogenesis induced by signal transducer and
activator of transcription 5A (STAT5A) is dependent on autocrine
activity of proliferin. J Biol Chem. 287:6490–6502. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29:(6 Suppl 16). S15–S18. 2002.
View Article : Google Scholar
|
17
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ucuzian AA and Greisler HP: In vitro
models of angiogenesis. World J Surg. 31:654–663. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Antoine M, Wirz W, Tag CG, Mavituna M,
Emans N, Korff T, Stoldt V, Gressner AM and Kiefer P: Expression
pattern of fibroblast growth factors (FGFs), their receptors and
antagonists in primary endothelial cells and vascular smooth muscle
cells. Growth Factors. 23:87–95. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Nilsson EM, Brokken LJ and Härkönen PL:
Fibroblast growth factor 8 increases breast cancer cell growth by
promoting cell cycle progression and by protecting against cell
death. Exp Cell Res. 316:800–812. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Matsumura I, Kitamura T, Wakao H, Tanaka
H, Hashimoto K, Albanese C, Downward J, Pestell RG and Kanakura Y:
Transcriptional regulation of the cyclin D1 promoter by STAT5: Its
involvement in cytokine-dependent growth of hematopoietic cells.
EMBO J. 18:1367–1377. 1999. View Article : Google Scholar : PubMed/NCBI
|
22
|
Dudley AC, Thomas D, Best J and Jenkins A:
A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell
tolerance to hypoxia. Biochem J. 390:427–436. 2005. View Article : Google Scholar : PubMed/NCBI
|
23
|
Klemke RL, Cai S, Giannini AL, Gallagher
PJ, de Lanerolle P and Cheresh DA: Regulation of cell motility by
mitogen-activated protein kinase. J Cell Biol. 137:481–492. 1997.
View Article : Google Scholar : PubMed/NCBI
|